Drug Trial Radar · NCT00667823
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
550
Actual
Start
Oct 17, 2008
Primary completion
Dec 7, 2020
Study completion Dec 7, 2020
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 28, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.
Conditions
- Pulmonary Arterial Hypertension
Interventions
MacitentanDrug
Tablet, oral administration, 10 mg dose once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to 12 years)
- Number of Participants With Death up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to 12 years)
- Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to 12 years)
- Number of Participants With AEs Leading to Permanent Discontinuation of Study TreatmentTime frame: Up to 28 days after study treatment discontinuation (Up to12 years)
- Number of Participants With Treatment Emergent Abnormal Liver Tests up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after study treatment discontinuation (Up to12 years)
- Number of Participants With Treatment Emergent Hemoglobin Abnormality up to 28 Days After Study Treatment DiscontinuationTime frame: Up to 28 days after treatment discontinuation (Up to 12 years)
Locations
158 sites in 36 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Pulmonary Specialists
Phoenix, Arizona
University of California, San Diego
La Jolla, California
GLVA Healthcare Center
Los Angeles, California
Santa Barbara Cottage Hospital
Santa Barbara, California
Liu Center for Pulmonary Hypertension
Torrance, California
University of Colorado CARDIAC AND VASCULAR CENTER
Aurora, Colorado
University of Florida - Division of Pulmonology
Gainesville, Florida
Mayo Clinic, Jacksonville
Jacksonville, Florida
Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease
Atlanta, Georgia
Pulmonary & Critical Care of Atlanta
Atlanta, Georgia
Atlanta Institute for Medical Research
Decatur, Georgia
University of Chicago
Chicago, Illinois
University of Iowa, Pulmonary Hypertension Program
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kentuckiana Pulmonary Associate, PLLC
Louisville, Kentucky
Louisiana State University Health Sciences Center
New Orleans, Louisiana
Maine Medical Center
Portland, Maine
University of Maryland School of Medicine; Division of Cardiology
Baltimore, Maryland
Pulmonary/Critical Care Division/Tufts New England Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Boston University School of Medicine
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Harper Univ. Hospital/ Wayne State University
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
University of NJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey
Columbia University Medical Center - Pediatric Cardiology
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Ohio Heart Health Center
Cincinnati, Ohio
Ohio State University, Div. of Pul. & Critical Care
Columbus, Ohio
Allegheny General Hospital
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Medical Center - St. Paul University
Dallas, Texas
Baylor College of Medicine and the Methodist Hospital,
Houston, Texas
University of Texas Houston Health Center
Houston, Texas
Intermountain Med Ctr- Pulm Dept Heart and Lung Ctr
Murray, Utah
Sentara Hospitals T/A Sentara Cardiovascular Research Intitute
Norfolk, Virginia
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin
Sanatorio MITRE
Buenos Aires, Argentina
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.